MORPHOSYS US INC
BiotechMORPHOSYS US INC is a biotechnology company focused on Oncology.
FDA Novel Drug Designations
(2020)See 1 novel approval →
MORPHOSYS US INC at a Glance
- Strong track record with 83% execution quality across 8 trials
MORPHOSYS US INC's Key Drugs
MORPHOSYS US INC's core commercial portfolio centers on MONJUVI, spanning Oncology — its most strategically important drugs approved in the last 15 years.
MORPHOSYS US INC's Recent FDA Approvals
New NDA/BLA approvals for MORPHOSYS US INC over the last two years — novel drugs only, excluding generics and label supplements.
MORPHOSYS US INC's Therapeutic Areas
MORPHOSYS US INC's approved drugs and pipeline span 1 therapeutic area, led by Oncology. Weighted by commercial stage — approved drugs count most, then late-stage trials.
MORPHOSYS US INC's Top Competitors
MORPHOSYS US INC's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Novartis, and Merck. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
MORPHOSYS US INC Pipeline Snapshot
Active clinical trials for MORPHOSYS US INC across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • MONJUVI leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 0/0 completed
- • Speed: 47 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2020-07-31
- Latest
- 2025-06-18
- Applications
- 1
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges